[go: up one dir, main page]

WO2003033494A1 - Benzimidazole derivative - Google Patents

Benzimidazole derivative Download PDF

Info

Publication number
WO2003033494A1
WO2003033494A1 PCT/JP2002/010706 JP0210706W WO03033494A1 WO 2003033494 A1 WO2003033494 A1 WO 2003033494A1 JP 0210706 W JP0210706 W JP 0210706W WO 03033494 A1 WO03033494 A1 WO 03033494A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
benzimidazole derivative
alkyl
represented
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010706
Other languages
French (fr)
Japanese (ja)
Inventor
Takashi Fujita
Kunio Wada
Tomoyuki Shibata
Shinichi Kurakata
Kosaku Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of WO2003033494A1 publication Critical patent/WO2003033494A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound having excellent inhibitory activity against cancer cells and useful as an antitumor agent, which is represented by the following general formula (I): (I) (wherein R1 represents C3-6 branched alkyl and R2 represents hydrogen or C1-6 alkyl); or a pharmacologically acceptable salt of the compound.
PCT/JP2002/010706 2001-10-17 2002-10-16 Benzimidazole derivative Ceased WO2003033494A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001319632 2001-10-17
JP2001-319632 2001-10-17

Publications (1)

Publication Number Publication Date
WO2003033494A1 true WO2003033494A1 (en) 2003-04-24

Family

ID=19137154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010706 Ceased WO2003033494A1 (en) 2001-10-17 2002-10-16 Benzimidazole derivative

Country Status (1)

Country Link
WO (1) WO2003033494A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US9925175B2 (en) 2007-09-26 2018-03-27 Deuterx, Llc Deuterium-enriched pioglitazone
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018081A1 (en) * 1997-10-08 1999-04-15 Sankyo Company, Limited Substituted fused heterocyclic compounds
WO2000061581A1 (en) * 1999-04-07 2000-10-19 Sankyo Company, Limited Amine derivatives
JP2000351769A (en) * 1999-04-07 2000-12-19 Sankyo Co Ltd Insulin resistance improver
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
WO2002013864A1 (en) * 2000-08-16 2002-02-21 Sankyo Company, Limited Medicinal compositions for preventing and treating cancer
JP2002179568A (en) * 2000-10-06 2002-06-26 Sankyo Co Ltd Prophylactic agent or therapeutic agent comprising amine derivative compound

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018081A1 (en) * 1997-10-08 1999-04-15 Sankyo Company, Limited Substituted fused heterocyclic compounds
WO2000061581A1 (en) * 1999-04-07 2000-10-19 Sankyo Company, Limited Amine derivatives
JP2000351769A (en) * 1999-04-07 2000-12-19 Sankyo Co Ltd Insulin resistance improver
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
WO2002013864A1 (en) * 2000-08-16 2002-02-21 Sankyo Company, Limited Medicinal compositions for preventing and treating cancer
JP2002179568A (en) * 2000-10-06 2002-06-26 Sankyo Co Ltd Prophylactic agent or therapeutic agent comprising amine derivative compound

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576071B2 (en) 2007-09-26 2020-03-03 Poxel Sa Deuterium-enriched pioglitazone
US10940143B2 (en) 2007-09-26 2021-03-09 Poxel Sa Deuterium-enriched pioglitazone
US9925175B2 (en) 2007-09-26 2018-03-27 Deuterx, Llc Deuterium-enriched pioglitazone
US11918567B2 (en) 2007-09-26 2024-03-05 Poxel Sa Deuterium-enriched pioglitazone
US9833445B2 (en) 2013-03-14 2017-12-05 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US10265305B2 (en) 2013-03-14 2019-04-23 Poxel Sa 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US11123336B2 (en) 2013-03-14 2021-09-21 Poxel Sa 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US9416117B2 (en) 2013-03-14 2016-08-16 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US11918569B2 (en) 2013-03-14 2024-03-05 Poxel Sa 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11141411B2 (en) 2014-01-15 2021-10-12 Poxel Sa Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Similar Documents

Publication Publication Date Title
MX2010003394A (en) Bicyclic ?“-amino acid derivative.
CA2481591A1 (en) Stabilized ascorbic acid derivatives
WO2009020140A1 (en) Adamantylurea derivative
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
HK1053831A1 (en) Kinase inhibitors as therapeutic agents
MX2007004215A (en) Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n- propyl-piperidine.
EP1889842A4 (en) Heterocyclic compound
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
MXPA02003977A (en) INHIBITORS OF agr;L.
EP1568699A4 (en) 1,3-dihydroimidazole fused-ring compound
AU2003229953A1 (en) Phthalazinone derivatives
TW200612958A (en) Substituted imidazole derivatives
MX2009006907A (en) Glucokinase-activating substance.
TW200740805A (en) Novel compounds
WO2009038064A1 (en) Heterocyclic derivative having inhibitory activity on type-i 11β-hydroxysteroid dehydrogenase
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
AU7824900A (en) Compounds and methods for inhibiting mrp1
WO2008105526A1 (en) Macrocyclic compound
WO2008139845A8 (en) Novel amide derivative
TW200637539A (en) CTGF inhibitors
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
TW200637561A (en) Antitumor agent
WO2003033494A1 (en) Benzimidazole derivative
DE60230781D1 (en) Reverse hydroxamsäurederivate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP